Clinical Study Of Autologous Bone Marrow Mesenchymal Stem Cells Transplantation In Treating Dilated Cardiomyopathy

Objective:To identify clinical efficacy in coronary transplantation of bone marrow mesenchymal stem cells(MSCs) for dilated cardiomyopathy(DCM).Method:38patients who had DCM with NYHAⅡ～Ⅳ class,myocardial perfusion defects and reduced<40%left ventricular ejection fraction (LVEF) were randomized to intracoronary infusion of MSCs (n=18) or the same amount of normal saline(n=20) through the5F coronary catheter.Change of left ventricular ejection fraction (LVEF), Left ventricular end-diastolic diameter (LVEDd) and perfusion defects of myocardium were assessed before and30±3d、90±7d after the proceduce respectively in all patients, in addition maligmant cardiovascular events by recording24h Holter.Result:①In one and three month, left ventricular ejection fraction (LVEF) in trial group was increased markedly compared with those pre-treating and control (P<0.05),and there was no significant difference in control group in one month compared with pre-treating (P>0.05);while there was significant difference between three month and pre-treating in control group(P<0.05).②Left ventricular end-diastolic diameter (LVEDD) in trail group was decreased in one month(P<0.05),but LVEDD in control group was increased compared with pre-treating (P<0.05), and there was significant difference between two groups (P<0.05). Compareing with those pre-treating and one month, LVEDD in trail group was decreased significantly in three month (P<0.05), but LVEDD in control group was increased compared with pre-treating (P<0.05), and there was also significant difference between two groups (P<0.05).③Comparing with those pre-treating, perfusion defects of myocardium in trail group and control was decreased in one month (P>0.05),while there was no significant difference between two groups (P>0.05). Comparing with those pre-treating and one month, perfusion defects of myocardium in trail group was decreased in three month(P<0.05), and there was significant difference compareing w between two groups (P<0.05).④There were no differences in malignant arrlythmia events between groups during follow-up. No death was recorded during the follow-up period.Conclusion:①Autologous bone marrow mesenchymal stem cells transplantation is safe in treating dilated cardiomyopathy(DCM);②Autologous bone marrow mesenchymal stem cells transplantation is effective in treating dilated cardiomyopathy(DCM).